The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification

BACKGROUND: With the widespread clinical application of tyrosine kinase inhibitors (TKIs), an increasing number of chronic myeloid leukaemia (CML) patients have developed resistance or intolerance to TKIs. BCR/ABL is the oncoprotein of CML. HSP90 is an essential chaperone of BCR/ABL and plays an imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Dachuan, Gao, Miao, Zheng, Renren, Qin, Run, He, Wei, Liu, Suotian, Wei, Wei, Huang, Zhenglan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137153/
https://www.ncbi.nlm.nih.gov/pubmed/35624462
http://dx.doi.org/10.1186/s40164-022-00287-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137153/
https://www.ncbi.nlm.nih.gov/pubmed/35624462
http://dx.doi.org/10.1186/s40164-022-00287-w

Ejemplares similares